

Ajinomoto Co., Inc.

Consolidated Results

IFRS

First Quarter Ended June 30, 2021

This document has been translated from the original Japanese as a guide for non-Japanese investors. It contains forward-looking statements based on a number of assumptions and judgements made by management in light of information currently available. Actual financial results may differ depending on a number of factors, including changing economic conditions, legislative and regulatory developments, delay in new product launches, and pricing and product initiatives of competitors.

SUMMARY OF FINANCIAL STATEMENTS [IFRS] (Consolidated)

First quarter results for the fiscal year ending March 31, 2022

Ajinomoto Co., Inc.

Stock Code: 2802	Stock exchange listing:	Tokyo Stock Exchange
URL: https://www.ajinomoto.co.jp/company/		
Representative: Takaaki Nishii		
		Representative Executive Officer & President
For inquiries: Eiichi Mizutani	Telephone:	+81-3-5250-8111
		Corporate Executive & General Manager
		Global Finance Department
Scheduled date of submission of statutory quarterly financial report:	August 6, 2021	
Scheduled date of starting payment of dividend:	—	
Creation of supplementary results materials:	Yes	
Results briefing:	Yes	

July 30, 2021

1. Consolidated Financial Results for the Three Months Ended June 30, 2021

(1) Consolidated Operating Results

	Three months ended June 30, 2021		Three months ended June 30, 2020	
	Change %		Change %	
Sales	276,338	11.5	247,927	(6.0)
Business profit	38,930	15.1	33,819	22.5
Profit before income taxes	34,940	0.5	34,751	29.5
Profit	23,923	(3.9)	24,904	29.9
Profit attributable to owners of the parent company	22,066	(1.3)	22,353	35.7
Basic earnings per share (yen)	¥40.23	—	¥40.78	—
Diluted earnings per share (yen)	¥40.23	—	¥40.75	—

Millions of yen, rounded down

“Change %” indicates the percentage change compared to the same period of the previous fiscal year.

Note: Upon the adoption of IFRS, the Ajinomoto Group has introduced “business profit” as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group’s business portfolio by the Board of Directors and the Management Committee. “Business profit” is defined as sales minus the cost of sales, selling expenses, research and development expenses, and general and administrative expenses, to which is then added share of profit of associates and joint ventures. Business profit does not include other operating income or other operating expenses.

(2) Consolidated Financial Position

	As of June 30, 2021	As of March 31, 2021
	Total assets	1,420,547
Total equity	676,911	667,846
Equity attributable to owners of the parent company	628,244	620,257
Ownership ratio attributable to owners of the parent company (%)	44.2%	43.3%

Millions of yen, rounded down

2. Dividends

	Fiscal year ended March 31, 2021	Fiscal year ending March 31, 2022	Fiscal year ending March 31, 2022 (forecast)
Dividend per share			
Interim (yen)	¥16.00		¥22.00
Year-end (yen)	¥26.00		¥22.00
Annual (yen)	¥42.00		¥44.00

Note: Revisions to dividend forecasts in the period under review: None

3. Forecast for the Fiscal Year Ending March 31, 2022

Millions of yen, rounded down

	Fiscal year ending March 31, 2022	
		Change %
Sales.....	1,113,000	3.9
Business profit	115,000	1.6
Profit attributable to owners of the parent company.....	60,000	1.0
Basic earnings per share (yen).....	¥111.25	—

"Change %" indicates the percentage change compared to the previous fiscal year.

Note: Revisions to forecasts in the period under review: None

Notes:

(1) Changes in significant subsidiaries during the period (Changes in specified subsidiaries resulting in a change in consolidation scope): Yes

Added: None

Excluded: one company: Ajinomoto Animal Nutrition Europe S.A.S.

(2) Changes in accounting policies and accounting estimates

1) Changes in accounting policies as required by IFRS: None

2) Other changes in accounting policies: None

3) Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

	<i>Shares</i>	
	As of June 30, 2021	As of March 31, 2021
Number of shares outstanding at end of period (including treasury shares):	549,163,354	549,163,354
Number of treasury shares at end of period	703,206	663,058
	April 1, 2021 to June 30, 2021	April 1, 2020 to June 30, 2020
Average number of shares during period	548,464,983	548,188,987

(Note) The number of treasury shares at the end of the period includes the Company's shares held by the director's remuneration BIP trust (As of June 30, 2021: 498,400 shares. As of March 31, 2021: 559,200 shares), which was adopted along with the introduction of stock-based remuneration of executive officers based on the company's medium-term earnings performance for the directors and others. In addition, these Company's shares are included in the treasury shares which are deducted from the number of shares outstanding at the end of the period when calculating the average number of shares during the period.

Summary quarterly financial statements are exempted from review by a public certified accountant or an auditing firm.

Appropriate use of forecasts and other notes

Disclaimer regarding forward-looking statements and other information

Forward-looking statements, such as business forecasts, included in this document are based on management's estimates, assumptions, and projections at the time of publication. These statements do not represent a promise or commitment by the Company to achieve these forecasts. Actual operating results may differ significantly due to various factors. For more information regarding our earnings forecasts, see page 10, "1. Qualitative Information on the Three Month Consolidated Results, (3) Explanation of Forecast Data, Including Consolidated Results Forecasts."

Where to obtain supplementary results materials

Supplementary results materials will be published on the Company's website on Friday, July 30, 2021.

Table of contents

1	Qualitative Information on the Three Month Consolidated Results.....	6
	(1) Overview of Operating Results	6
	(2) Overview of Financial Position.....	10
	(3) Explanation of Forecast Data, including Consolidated Results Forecasts	10
2	Condensed Consolidated Financial Statements and Notes.....	11
	(1) Condensed Consolidated Statements of Financial Position	11
	(2) Condensed Consolidated Statements of Income	13
	For the First Quarter	13
	(3) Notes to Condensed Consolidated Financial Statements	14
	Going Concern Assumption	14
	Significant Accounting Policies	14
	Segment Information.....	15

1. Qualitative Information on the Three Month Consolidated Results

Upon the adoption of IFRS, the Ajinomoto Group has introduced "business profit" as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continuous evaluation of the Group's business portfolio by the Board of Directors and the Management Committee. "Business profit" is defined as sales minus the cost of sales, selling expenses, research and development expenses, and general and administrative expenses, to which is then added share of profit of associates and joint ventures. Business profit does not include other operating income or other operating expenses.

(1) Overview of Operating Results

In the three-months ended June 30, 2021, the Company's consolidated sales increased 11.5% year-on-year, or ¥28.4 billion, to ¥276.3 billion. This was mainly the result of strong sales in Seasonings and Foods and Frozen Foods overseas, of home-use products, and a partial recovery in sales of restaurant and industrial use products which were affected by the COVID-19 pandemic in the previous fiscal year, in addition to a large increase in revenue in Healthcare and Others. Business profit increased 15.1% year-on-year, or ¥5.1 billion, to ¥38.9 billion because of the large increase in profit in Healthcare and Others, despite the impact from the strategic use of marketing expenses and higher raw material prices in Seasonings and Foods and Frozen Foods. Profit attributable to owners of the parent company totaled ¥22.0 billion, down 1.3% year-on-year, or ¥0.2 billion, mainly due to expenses related to the sale of the animal nutrition business in Europe recorded in other operating expenses.

Consolidated operating results by segment

Results for individual business segments are summarized below.

Versus previous year results	<i>Billions of yen, rounded down</i>					
	Sales			Business profit		
	FY2021 First Qtr.	YoY change - amount	YoY change	FY2021 First Qtr.	YoY change - amount	YoY change
Seasonings and Foods	157.5	15.1	10.7 %	24.2	0.4	1.7%
Frozen Foods	52.4	4.2	8.8 %	0.9	(0.9)	(48.9)%
Healthcare and Others	63.5	9.5	17.7 %	12.7	5.2	70.0%
Other	2.7	(0.5)	(17.8)%	0.9	0.3	65.2%
Total	276.3	28.4	11.5 %	38.9	5.1	15.1%

Versus the forecast	<i>Billions of yen, rounded down</i>					
	Sales			Business profit		
	FY2021 First Qtr.	Forecast for the year	Achieved - percent	FY2021 First Qtr.	Forecast for the year	Achieved - percent
Seasonings and Foods	157.5	654.7	24.1%	24.2	85.8	28.3%
Frozen Foods	52.4	208.2	25.2%	0.9	2.4	39.1%
Healthcare and Others	63.5	231.3	27.5%	12.7	29.2	43.4%
Other	2.7	18.6	14.6%	0.9	(2.6)	—
Total	276.3	1,113.0	24.8%	38.9	115.0	33.9%

1) Seasonings and Foods

In the Seasonings and Foods segment, sales increased 10.7% year-on-year, or ¥15.1 billion, to ¥157.5 billion, largely because of strong sales of home-use products and the partial recovery in sales of restaurant and commercial use products, which were affected by the COVID-19 pandemic in the previous fiscal year, both overseas. Segment business profit increased 1.7% year-on-year, or ¥0.4 billion, to ¥24.2 billion, owing to the effect of increased overseas revenue and other factors, despite the impact from the strategic use of marketing expenses and higher raw material prices.



Main factors affecting segment sales

Sauce & Seasonings: Large increase in revenue due to strong sales of home-use products and recovery of foodservice-use products in some channels, both overseas, despite being level with the previous year in Japan.

In Japan, revenue was level with the previous year due to the fall back in at-home demand after the rapid rise in the previous year, despite effective sales promotion activities.


Overseas, revenue increased significantly due to strong sales of home-use products accompanying strong at-home demand and recovery of sales of foodservice-use products in some channels.

Quick Nourishment: Increase in revenue due to increased sales of soup products in Japan as well as instant noodles and beverages overseas.

In Japan, revenue increased due to increased sales of soup products against the backdrop of continued growing demand.

Overseas, revenue increased significantly due to increased sales of instant noodles and beverages.

Solution & Ingredients: Increase in revenue due to increased sales of umami seasonings for processed food manufacturers worldwide and foodservice-use products in Japan.



Main factors affecting segment profits

Sauce & Seasonings: Increase in profit due to increased revenue overseas, despite strategic use of marketing expenses and the effect of rising raw material prices in Japan.

In Japan, large decrease in profit due to strategic use of marketing expenses and the effect of rising raw material prices, despite sales being level with the previous year.

Overseas, large increase in profit due to the effect of increased revenue.

Quick Nourishment: Increase in profit due to the effect of increased revenue overseas, despite the launch of a new factory and the effect of strategic use of marketing expenses, both in Japan.

In Japan, decrease in profit due to the effect of launching a new factory and strategic use of marketing expenses.


Overseas, large increase in profit due to large increase in revenue.

Solution & Ingredients: Large decrease in profit due to the impact of rising raw material and fuel costs for umami seasonings for processed food manufacturers, despite increased revenue.

2) Frozen Foods

Frozen Foods segment sales increased 8.8% year-on-year, or ¥4.2 billion, to ¥52.4 billion, largely owing to the increase in sales of industrial-use products overseas. Segment business profit decreased 48.9% year-on-year, or ¥0.9 billion, to ¥0.9 billion, due to the strategic use of marketing expenses in Japan and higher costs, including personnel expenses, as well as other factors in North America.

Sales (¥bil)



Main factors affecting segment sales

Increase in revenue overall due to significantly increased revenue in North America and Europe because of increased sales, despite decreased revenue in Japan due to the impact of structural reform. In Japan, revenue decreased due to the impact of ceasing sales accompanying structural reform, despite increased sales of high-value-added products.

Overseas, revenue increased significantly due to the rapid recovery of restaurant-use products and continued steady demand for home-use products in North America as well as increased sales centered on mainstay products in Europe.

Business Profit (¥bil)



Main factors affecting segment profits

Large decrease in profit due to strategic use of marketing expenses in Japan and increased costs in North America, despite increased revenue.

In Japan, decrease in profit due to strategic use of marketing expenses.


Overseas, large decrease in profit due to rising labor costs, raw material prices, and logistics costs in North America, despite significantly increased revenue.

3) Healthcare and Others

Healthcare and Others segment sales increased 17.7% year-on-year, or ¥9.5 billion, to ¥63.5 billion, owing to a significant increase in sales in Bio-Pharma Services & Ingredients and Functional Materials, despite the large decline in revenue for animal nutrition products due to the impact of structural reform. Segment business profit increased 70.0% year-on-year, or ¥5.2 billion, to ¥12.7 billion due to the effect of revenue growth.

In the quarter ended June 30, 2021, the Company changed the names and product classifications of some of its product categories. For more details, see “2 Condensed Consolidated Financial Statements and Notes, 3 Notes to Condensed Consolidated Financial Statements, Segment Information.” In addition, in the quarter ended June 30, 2021, the Amino Acids for Pharmaceuticals and Foods and Bio-Pharma Services businesses were combined and reclassified as the Bio-Pharma Services & Ingredients business.

Sales (¥bil)




Main factors affecting segment sales

Bio-Pharma Services & Ingredients: Overall large increase in revenue due to increased sales of Amino Acids for Pharmaceuticals and Foods and Bio-Pharma Services.

Functional Materials: Large increase in revenue primarily due to strong sales of electronic materials.

Others: Increase in revenue due to increased sales of personal care ingredients and sports nutrition, despite large decrease in revenue for animal nutrition due to the impact of structural reform.

Business Profit (¥bil)



Main factors affecting segment profits

Bio-Pharma Services & Ingredients: Large increase in profit accompanying large increase in revenue.

Functional Materials: Large increase in profit accompanying large increase in revenue.

Others: Large increase in profit due to the effects of increased revenue.

4) Other

In the Other segment, sales totaled ¥2.7 billion, down 17.8% year-on-year, or ¥0.5 billion. Segment business profit totaled ¥0.9 billion, up 65.2% year-on-year, or ¥0.3 billion.

(2) Overview of Financial Position

As of June 30, 2021, the Company's consolidated total assets stood at ¥1,420.5 billion, a decrease of ¥10.7 billion from ¥1,431.2 billion at the end of the previous fiscal year on March 31, 2021. The main reason for this was the sale of the animal nutrition business in Europe accompanying structural reform of the animal nutrition business.

Total liabilities came to ¥743.6 billion, ¥19.8 billion less than the ¥763.4 billion at the end of the previous fiscal year, mainly due to a decrease in trade and other payables and the sale of the animal nutrition business in Europe, despite an increase in interest-bearing debt. Interest-bearing debt totaled ¥429.3 billion, an increase of ¥22.4 billion from the end of the previous fiscal year, mainly reflecting an increase in commercial papers.

Total equity as of June 30, 2021 was ¥9.0 billion more than at the end of the previous fiscal year, mainly reflecting an increase in retained earnings. Equity attributable to owners of the parent company, which is total equity minus non-controlling interests, totaled ¥628.2 billion, and the equity ratio attributable to owners of the parent company was 44.2%.

(3) Explanation of Forecast Data, including Consolidated Results Forecasts

The Company has not revised the results forecasts published on May 10, 2021.

2. Condensed Consolidated Financial Statements and Notes

(1) Condensed Consolidated Statements of Financial Position

	<i>Millions of yen</i>	
	As of end of first quarter (June 30, 2021)	As of end of previous fiscal year (March 31, 2021)
Assets		
Current assets		
Cash and cash equivalents	180,514	181,609
Trade and other receivables	153,231	162,104
Other financial assets	20,566	12,078
Inventories	200,603	188,664
Income taxes receivable	11,804	7,459
Others	19,967	18,746
Subtotal	586,688	570,662
Assets of disposal groups classified as held for sale	—	14,506
Total current assets	586,688	585,169
Non-current assets		
Property, plant and equipment	486,751	486,443
Intangible assets	71,583	72,201
Goodwill	96,007	96,024
Investments in associates and joint ventures	113,389	112,246
Long-term financial assets	48,749	53,576
Deferred tax assets	7,270	14,537
Others	10,107	11,090
Total non-current assets	833,859	846,119
Total assets	1,420,547	1,431,289

	As of end of first quarter (June 30, 2021)	As of end of previous fiscal year (March 31, 2021)
Liabilities		
Current liabilities		
Trade and other payables	161,975	188,452
Short-term borrowings	24,430	10,820
Commercial papers	50,000	30,000
Current portion of long-term borrowings	17,756	18,085
Other financial liabilities	11,839	11,603
Short-term employee benefits	37,745	38,288
Provisions	1,683	4,343
Income taxes payable	15,076	10,770
Others	15,159	11,371
Subtotal	335,666	323,736
Liabilities of disposal groups classified as held for sale	—	12,603
Total current liabilities	335,666	336,339
Non-current liabilities		
Corporate bonds	149,622	149,608
Long-term borrowings	136,876	141,911
Other financial liabilities	65,118	69,381
Long-term employee benefits	42,877	43,487
Provisions	4,738	4,704
Deferred tax liabilities	7,088	16,240
Others	1,646	1,770
Total non-current liabilities	407,968	427,103
Total liabilities	743,635	763,443
Equity		
Common stock	79,863	79,863
Capital surplus	(996)	—
Treasury stock	(1,569)	(1,464)
Retained earnings	616,346	608,031
Other components of equity	(65,399)	(65,454)
Other components of equity related to disposal groups classified as held for sale	—	(718)
Equity attributable to owners of the parent company	628,244	620,257
Non-controlling interests	48,666	47,589
Total equity	676,911	667,846
Total liabilities and equity	1,420,547	1,431,289

(2) Condensed Consolidated Statements of Income
For the First Quarter
Millions of yen

	Three months (April 1, 2021 to June 30, 2021)	Three months (April 1, 2020 to June 30, 2020)
Sales	276,338	247,927
Cost of sales	(167,548)	(149,728)
Gross profit	108,790	98,199
Share of profit of associates and joint ventures	1,981	1,050
Selling expenses	(38,448)	(34,745)
Research and development expenses	(6,364)	(6,375)
General and administrative expenses	(27,029)	(24,309)
Business profit	38,930	33,819
Other operating income	1,728	4,054
Other operating expenses	(4,315)	(2,408)
Operating profit	36,343	35,465
Financial income	1,000	1,173
Financial expenses	(2,402)	(1,887)
Profit before income taxes	34,940	34,751
Income taxes	(11,016)	(9,847)
Profit	23,923	24,904
Attributable to:		
Owners of the parent company	22,066	22,353
Non-controlling interests	1,857	2,550
Earnings per share (yen):		
Basic	¥40.23	¥40.78
Diluted	¥40.23	¥40.75

(3) Notes to Condensed Consolidated Financial Statements

Going Concern Assumption

Not applicable

Significant Accounting Policies

The significant accounting policies used to prepare these condensed consolidated financial statements for the three months are unchanged from the policies applied to the consolidated financial statements in the previous fiscal year. Income taxes for these three-months are calculated based on an estimation of the effective tax rate for the fiscal year.

Impact of Applying New Accounting Policies: Not applicable

Segment Information

(1) Overview of reportable segments

The Group's reportable segments are categorized primarily by product lines. There are three reportable segments: Seasonings and Foods, Frozen Foods, and Healthcare and Others.

Each reportable segment is a component of the Group for which separate financial information is available and evaluated regularly by the Management Committee in determining the allocation of management resources and in assessing performance.

The product categories belonging to each reportable segment are as follows:

Reportable Segments	Details	Main Products
Seasonings and Foods	Sauce and Seasonings	Umami seasonings <i>AJI-NO-MOTO</i> [®] , <i>HON-DASHI</i> [®] , <i>Cook Do</i> [®] , <i>Ajinomoto KK Consommé</i> , <i>Pure Select</i> [®] <i>Mayonnaise</i> , <i>Ros Dee</i> [®] (flavor seasoning/Thailand), <i>Masako</i> [®] (flavor seasoning/Indonesia), <i>Aji-ngon</i> [®] (flavor seasoning/Vietnam), <i>Sazón</i> [®] (flavor seasoning/Brazil), <i>Sajiku</i> (menu-specific seasoning/Indonesia), <i>CRISPY FRY</i> (menu-specific seasoning/Philippines), etc.
	Quick Nourishment	<i>Knorr</i> [®] <i>Cup Soup</i> , <i>YumYum</i> [®] (instant noodles/Thailand), <i>Birdy</i> [®] (coffee beverage/Thailand), <i>Birdy</i> [®] <i>3in1</i> (powdered drink/Thailand), <i>Blendy</i> [®] brand products (<i>CAFÉ LATORY</i> [®] , stick coffee, etc.), <i>MAXIM</i> [®] brand products, <i>Chotto Zeitakuna Kohiten</i> [®] brand products, various gift sets, office supplies (coffee vending machines, tea servers), etc.
	Solution and Ingredients	Umami seasoning <i>AJI-NO-MOTO</i> [®] for foodservice and processed food manufacturers in Japan, Seasonings and processed foods for foodservice, Seasonings for processed foods (savory seasonings, enzyme <i>ACTIVA</i> [®]), Drinks supplied to restaurants, Ingredients for industrial use, Delicatessen products, Bakery products, Nucleotides, Sweeteners (aspartame for food processing, <i>PAL SWEET</i> [®] for home use, etc.), and others
Frozen Foods	Frozen Foods	Chinese dumplings (<i>Gyoza</i> , <i>Shoga Gyoza</i> , <i>POT STICKERS</i> , etc.), Cooked rice (<i>THE CHA-HAN</i> , <i>CHICKEN FRIED RICE</i> , <i>YAKITORI CHICKEN FRIED RICE</i> , etc.), Noodles (<i>YAKISOBA</i> , <i>RAMEN</i> , etc.), Desserts (cakes for restaurant and industrial-use, <i>MACARON</i> , etc.), Shumai (<i>THE SHUMAI</i> , etc.), Processed chicken (<i>Yawaraka Wakadori Kara-Age</i> (fried chicken), <i>THE KARAAGE</i> , etc.), and others
Healthcare and Others	Amino Acids for Pharmaceuticals and Foods	Amino acids, culture media
	Bio-Pharma Services	Contract manufacturing services of pharmaceutical intermediates and active ingredients, sterile products (fill and finish), etc.
	Functional Materials	Electronic materials (<i>Ajinomoto Build-up Film</i> [®] (ABF) interlayer insulating material for semiconductor packages and others), Functional materials (adhesive <i>PLENSET</i> [®]), Magnetic materials (<i>AFTINNOVA</i> [®] <i>Magnetic Film</i> and others), activated carbon, release paper, etc.

	Others	Feed-use amino acids (Lysine, Threonine, Tryptophan, Valine, <i>AjiPro</i> [®] -L, etc.), Fundamental Foods (<i>Glyna</i> [®] , <i>Amino Aile</i> [®]), Functional foods and drinks (<i>amino VITAL</i> [®]), Personal Care ingredients (amino acid-based mild surfactant <i>Amisoft</i> [®] , <i>Amilite</i> [®] , amino acid-based humectant <i>Ajidew</i> [®] , etc.) Medical foods, and others
--	--------	---

From the quarter ended June 30, 2021, medical foods, which was previously included in Amino Acids for Pharmaceuticals and Foods in Healthcare and Others, and some of the businesses previously included in Bio-Pharma Services in Healthcare and Others were included in Others in Healthcare and Others.

In addition, the name of the product category previously classified as Specialty Chemicals was changed to Functional Materials.

(2) Sales and earnings by segment

The Group's sales and earnings by reportable segment are as follows.

Inter-segment sales and transfers are primarily based on transaction prices between third-parties.

Three-months ended June 30, 2021 (April 1, 2021 to June 30, 2021)

Millions of yen

	Reportable segment			Other ¹	Total	Adjustments ²	As included in consolidated statements of income
	Seasonings and Foods	Frozen Foods	Healthcare and Others				
Sales							
Sales to third parties	157,521	52,499	63,593	2,725	276,338	—	276,338
Inter-segment sales and transfers	1,542	8	1,055	6,275	8,882	(8,882)	—
Total sales	159,063	52,507	64,648	9,001	285,221	(8,882)	276,338
Share of profit of associates and joint ventures	367	—	6	1,608	1,981	—	1,981
Segment profit or loss (Business profit or loss)	24,299	959	12,710	960	38,930	—	38,930
	Other operating income						1,728
	Other operating expense						(4,315)
	Operating profit						36,343
	Financial income						1,000
	Financial expense						(2,402)
	Profit before income taxes						34,940

1. Other includes the tie-up and other service-related businesses.

2. Common corporate expenses that are not attributed to specific reportable segments are allocated to each reportable segment based on reasonable criteria. Common corporate expenses mainly relate to the parent company's administrative divisions.

Three-months ended June 30, 2020 (April 1, 2020 to June 30, 2020)

Millions of yen

	Reportable segment			Other ¹	Total	Adjustments ²	As included in consolidated statements of income
	Seasonings and Foods	Frozen Foods	Healthcare and Others				
Sales							
Sales to third parties	142,323	48,262	54,023	3,317	247,927	—	247,927
Inter-segment sales and transfers	1,625	287	1,150	9,488	12,552	(12,552)	—
Total sales	143,949	48,549	55,174	12,806	260,479	(12,552)	247,927
Share of profit of associates and joint ventures	344	—	78	627	1,050	—	1,050
Segment profit or loss (Business profit or loss)	23,882	1,877	7,477	581	33,819	—	33,819
	Other operating income						4,054
	Other operating expense						(2,408)
	Operating profit						35,465
	Financial income						1,173
	Financial expense						(1,887)
	Profit before income taxes						34,751

1. Other includes the tie-up and other service-related businesses.

2. Common corporate expenses that are not attributed to specific reportable segments are allocated to each reportable segment based on reasonable criteria. Common corporate expenses mainly relate to the parent company's administrative divisions.